

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



VIVA BIOTECH HOLDINGS

维亚生物科技控股集团

(Incorporated in the Cayman Islands as an exempted company with limited liability)
(Stock code: 1873)

MAJOR TRANSACTION FURTHER DELAY IN DISPATCH OF CIRCULAR, APPLICATION FOR A WAIVER UNDER RULE 14.41(A) OF THE LISTING RULES AND EXTENSION OF THE LONGSTOP DATE

References are made to the announcement of Viva Biotech Holdings (the “**Company**”) dated September 21, 2020 in relation to the acquisition of the entire equity interest in SYNthesis med chem (Hong Kong) Limited for approximately US\$80 million (the “**Acquisition Announcement**”) and the announcement dated October 15, 2020 in relation to the grant by the Stock Exchange of the waiver from strict compliance with Rule 14.41(a) of the Listing Rules and delay in dispatch of the Circular (the “**Delay Announcement**”). Capitalized terms used herein have the same meanings as defined in the Acquisition Announcement and the Delay Announcement unless the context requires otherwise.

As the Acquisition was approved by way of written Shareholders’ approval, as disclosed in the Acquisition Announcement, pursuant to Rule 14.41(a) of the Listing Rules, the Circular is required to be dispatched to the Shareholders within 15 business days after the publication of the Acquisition Announcement (which was October 13, 2020). As disclosed in the Delay Announcement, the Company had previously applied for, and the Stock Exchange has granted a waiver from strict compliance with Rule 14.41(a) of the Listing Rules on the condition that the Company will dispatch the Circular to the Shareholders on or before December 15, 2020.

Additional time is required to for preparation of historical financial information to be included in the Circular, performing audit work and other procedures. The delay is primarily due to COVID-19 affecting the collection of audit evidence such as external confirmation from banks and third parties located in areas outside of the PRC. An application has been made by the Company to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules to further delay the dispatch of the Circular. The Company will make an announcement on the status of the waiver application and dispatch date of the Circular as and when appropriate.

As also disclosed in the Acquisition Announcement, the Longstop Date has been fixed on December 31, 2020. On December 15, 2020, the Vendor and the Company has entered into an amendment agreement pursuant to which both parties have agreed that the Longstop Date of the Agreement be extended to February 28, 2021. Save for the extension of the Longstop Date and necessary closing logistics to facilitate extension of the Longstop Date, all other terms of the Agreement shall remain unchanged.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, December 15, 2020

As at the date of this announcement, the Board comprises four Executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; a Non-executive Director, namely, Ms. Sun Yanyan; and three Independent Non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.